Cagricema

Product

by Novo Nordisk

CagriSema is an investigational once-weekly fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is being developed to support weight management and treatment of type 2 diabetes by reducing body weight and improving glycemic control.